KALA BIO, Inc. (KALA) company profile
Close on Nov 17, 2026Market cap $66.34MP/E –Yield –
About Kala Bio
Pharmaceutical Preparations, SIC 2834
KALA BIO, Inc. is a transitioning biopharmaceutical company that focuses on developing an on-premises artificial intelligence infrastructure platform tailored for the biotechnology and pharmaceutical sectors. Operating through its licensed Researgency platform, the company intends to provide platform-as-a-service offerings, implementation support, data analytics, and maintenance subscriptions. These tools allow biotechnology firms, pharmaceutical enterprises, and contract research organizations to analyze biological datasets, coordinate research workflows, and preserve data sovereignty within private environments. Concurrently, the company seeks to monetize its proprietary mesenchymal stem cell secretome biologics portfolio through licensing, sales, or partnerships following the discontinuation of its clinical-stage candidate KPI-012.
Historically, the enterprise conducted preclinical evaluations and clinical trials across 45 sites in the United States, alongside additional operations initiated in Mexico and Argentina. The provided filing text does not report current employee headcount, facility figures, or active corporate headquarters locations.
Summary of the business section of Kala Bio's latest annual report, written by StockData.
Company profile
Company
- Legal name
- KALA BIO, Inc.
- Founded
- 2009
- Headquarters
- Arlington, MA
- Address
- 1167 Massachusetts Avenue 02476
- Phone
- (781) 996-5252
- Website
- www.kalarx.com
- Employees
- 6, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- HTL International, LLC, Houston, Texas
Stock & identifiers
- Ticker
- KALA
- Exchange
- Nasdaq
- IPO date
- Jul 20, 2017
- Shares outstanding
- 19M, Aug 14, 2026
- Public float
- $24.60M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-50 reverse, May 11, 2026; 1-for-50 reverse, Oct 21, 2022
- SEC CIK
- 1479419
- CUSIP
- 483119301
- ISIN
- US4831193010
- FIGI
- BBG001J2MVT8
- Share class FIGI
- BBG001V0GBM6
- LEI
- 529900Y7RO0C9P0TX474
- EIN
- 27-0604595
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Avraham Minkowitz | Chief Executive Officer, Director | – |
| David E. Lazar | Chief Executive Officer, Director | 0 |
| Romulus K. Brazzell | SEE REMARKS | 35,952 |
| Mary Reumuth | CHIEF FINANCIAL OFFICER | 28,906 |
| Darius Kharabi | CHIEF BUSINESS OFFICER | 41,760 |
| Brendan P. Purdy | Director | – |
| Yonatan C. Colman | Director | – |
| Chaim D. Berger | Director | – |
| Hillel D. Posen | Director | – |
| Todd Bazemore | Director | 35,933 |
| Mark T. Iwicki | Director | 103,540 |
| Andrew I. Koven | Director | 16,972 |
| Howard B. Rosen | Director | 16,502 |
| Gregory D. Perry | Director | 13,344 |
| C. Daniel Myers | Director | 10,374 |
| Marjan Farid | Director | 10,242 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $906.64K | -$1.01M | $2.42M | $1 | – |
| FY2024 | $1.49M | $1.26M | $935.12K | $7 | – |
| FY2023 | $8.34M | $3.75M | $2.93M | $2 | – |
| FY2022 | $1.87M | $1.22M | $1.01M | $11 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Stock awards | Option awards | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|
| Mark Iwicki Former Chief Executive Officer | $111.87K | – | $166.41K | $627.47K | $896 | $906.64K | -39% |
| Todd Bazemore Former Interim Chief Executive Officer, President and Chief Operating Officer | $489.11K | $585.45K | $76.05K | $2.26M | $64.15K | $3.48M | +266% |
| Kim Brazzell Former Head of Research and Development and Chief Medical Officer | $420.00K | $522.00K | $76.05K | $285.04K | $55.08K | $1.36M | +48% |
| Mary Reumuth Former Chief Financial Officer | $438.96K | $475.55K | $76.05K | $285.04K | $47.00K | $1.32M | +70% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Jul 20, 2017
- Offer price
- $15.00
- Securities offered
- 6,000,000
- Gross proceeds
- $90.00M
- Exchange
- Nasdaq
- First trading day
- Jul 20, 2017
- First-day close
- $18.49+23.3%
- Lock-up ends (est.)
- Jan 16, 2018
“The initial public offering price is $15.00 per share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025 and March 31, 2026, we had a total of 6 full-time employees.”
Corporate history
Events identified from SEC filings
See a number that looks wrong?